Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
A holder of OMER common stock has filed a notice of proposed sale of 30,000 shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an indicated aggregate market value of 369,315.00, and there were 70,900,459 shares outstanding at the time of the notice.
The 30,000 shares to be sold were acquired on 01/13/2026 by exercising stock options under a registered plan, paid for in cash on the same date. The filing also shows that David J Borges sold an additional 30,000 common shares on 01/12/2026 for gross proceeds of 381,600.00 during the prior three months.
A shareholder of OMER has filed a notice of proposed sales of common stock under Rule 144. The filing indicates an intention to sell 30,000 common shares through Morgan Stanley Smith Barney LLC on or about 01/12/2026 on the NASDAQ, with an indicated aggregate market value of $381,600.00. The shares relate to prior open market purchases of 10,000 shares on 05/15/2022 and 20,000 shares on 11/14/2023, both paid in cash. The document notes that the person signing represents they are not aware of undisclosed material adverse information about the issuer.
Omeros Corporation disclosed preliminary year-end liquidity figures following an investor call. The company reported that at December 31, 2025, it had approximately $171.5 million in cash and short-term investments available for operations. This amount is described as preliminary and unaudited and may change after the company completes its customary financial closing procedures and adjustments.
The disclosure is provided under a current report and is specifically designated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions and will not automatically be incorporated into other securities filings.
Omeros Corporation reported that the U.S. Food and Drug Administration has approved YARTEMLEA® (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a serious and often fatal complication of stem-cell transplantation linked to activation of the lectin pathway of complement. The company issued a revised press release on December 24, 2025 to update the date of its YARTEMLEA approval-related conference call and to add supplemental information about the experts quoted, with no other changes to the release.
Omeros Corporation launched an at-the-market offering of up to $150,000,000 of common stock under a Controlled Equity Offering agreement with Cantor Fitzgerald as sales agent. Shares may be sold from time to time on Nasdaq or through negotiated transactions, with Cantor earning up to 3.0% of the gross sales price per share.
Proceeds will be used for general corporate purposes, including clinical and pre-clinical development, commercialization activities, working capital, potential debt repayment, acquisitions or investments, and other capital expenditures. As context, based on the November 13, 2025 closing price of $6.28, the company illustrates a maximum of 23,885,350 shares. Omeros reported 70,073,622 shares outstanding as of September 30, 2025, and provides an example showing 93,958,972 shares if the full amount were sold at that price. Estimated offering expenses are approximately $300,000.
Omeros Corporation reported a wider third‑quarter net loss while managing liquidity and advancing key transactions. For Q3 2025, net loss was $30.9 million, including a $21.2 million loss from continuing operations and a $9.7 million loss from discontinued operations. Operating costs eased year over year, with R&D $16.0 million (down from $24.1 million) and SG&A $10.4 million (down from $11.3 million).
As of September 30, 2025, cash, cash equivalents, and short‑term investments totaled $36.1 million, and cash used in operations for the nine months was $76.3 million. Shareholders’ deficit was $220.5 million. The company disclosed substantial doubt about its ability to continue as a going concern absent additional financing, asset sales, or closing its pending transaction.
On October 10, 2025, Omeros signed an Asset Purchase and License Agreement with Novo Nordisk, eligible for $340.0 million in upfront and near‑term payments, including $240.0 million at closing, plus up to $410.0 million in development/approval milestones, up to $1.3 billion in sales milestones, and tiered royalties. The transaction is expected to close in Q4 2025. The FDA target action date for narsoplimab in TA‑TMA was extended to December 26, 2025; an EU opinion is expected mid‑2026.
Omeros Corporation filed a current report to furnish its latest quarterly results. The company issued a press release on November 13, 2025, covering financial results for the three and nine months ended September 30, 2025, and attached this release as Exhibit 99.1.
The report clarifies that the press release and related information are being furnished, not filed, under securities laws, limiting associated liability and preventing automatic incorporation into other regulatory filings unless specifically included.
Omeros entered an Asset Purchase and License Agreement with Novo Nordisk granting exclusive global rights to develop and commercialize zaltenibart (OMS906) and related compounds. Omeros is eligible for up to $2.1 billion, including an upfront cash payment of $240.0 million at closing, up to $510 million in development and approval milestones, and up to $1.3 billion in sales-based milestones. The agreement also provides for tiered royalties on annual net sales at percentage rates ranging from high single digit to high teens.
The transaction is subject to customary conditions, including HSR waiting period expiration or termination, accuracy of representations, covenant compliance, and the absence of a material adverse effect, and is expected to close in the fourth quarter of 2025. At closing, a portion of the $240.0 million will repay the $67.1 million outstanding term loan under the 2024 Credit Agreement, along with related prepayment premiums and accrued interest, releasing all liens and covenants. Omeros retains certain MASP‑3 program rights, including small‑molecule development, and will provide transition services reimbursed by Novo Nordisk.
Omeros (OMER) reported an insider transaction by Chairman, CEO & President Gregory A. Demopulos. On October 13, 2025, he made bona fide gifts of common stock—300,000 shares each—to two irrevocable trusts established for the benefit of his minor children at a reported price of $0 (transaction code G).
Following these gifts, he directly holds 1,426,986 shares. Indirect holdings include 300,000 shares in each child trust and 123,945 shares held by his spouse. He disclaims beneficial ownership of the trust and spouse shares except to the extent of any pecuniary interest.